vs
BEAZER HOMES USA INC（BZH）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
Revvity的季度营收约是BEAZER HOMES USA INC的1.9倍（$772.1M vs $409.8M），Revvity同比增速更快（5.9% vs -47.0%），过去两年Revvity的营收复合增速更高（9.0% vs -28.7%）
比泽尔美国住宅公司是总部位于美国佐治亚州亚特兰大的住宅建筑企业，业务覆盖美国13个州。按竣工交付住宅数量统计，该公司在2016年是美国第十一大住宅建筑商，在美国本土住宅开发建设领域拥有较高的行业地位。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
BZH vs RVTY — 直观对比
营收规模更大
RVTY
是对方的1.9倍
$409.8M
营收增速更快
RVTY
高出52.9%
-47.0%
两年增速更快
RVTY
近两年复合增速
-28.7%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $409.8M | $772.1M |
| 净利润 | — | $98.4M |
| 毛利率 | 11.9% | — |
| 营业利润率 | — | 14.5% |
| 净利率 | — | 12.7% |
| 营收同比 | -47.0% | 5.9% |
| 净利润同比 | — | 3.9% |
| 每股收益（稀释后） | $-0.03 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BZHRVTY
| Q2 26 | $409.8M | — | ||
| Q1 26 | $363.5M | — | ||
| Q4 25 | $363.5M | $772.1M | ||
| Q3 25 | $791.9M | $698.9M | ||
| Q2 25 | $545.4M | $720.3M | ||
| Q1 25 | $565.3M | $664.8M | ||
| Q4 24 | $469.0M | $729.4M | ||
| Q3 24 | $806.2M | $684.0M |
净利润BZHRVTY
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $-32.6M | $98.4M | ||
| Q3 25 | $30.0M | $46.7M | ||
| Q2 25 | $-324.0K | $53.9M | ||
| Q1 25 | $12.8M | $42.2M | ||
| Q4 24 | $3.1M | $94.6M | ||
| Q3 24 | $52.1M | $94.4M |
毛利率BZHRVTY
| Q2 26 | 11.9% | — | ||
| Q1 26 | 10.2% | — | ||
| Q4 25 | 10.2% | — | ||
| Q3 25 | 13.5% | 53.6% | ||
| Q2 25 | 13.3% | 54.5% | ||
| Q1 25 | 15.2% | 56.5% | ||
| Q4 24 | 15.4% | — | ||
| Q3 24 | 17.5% | 56.3% |
营业利润率BZHRVTY
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | -8.8% | 14.5% | ||
| Q3 25 | 3.1% | 11.7% | ||
| Q2 25 | -0.7% | 12.6% | ||
| Q1 25 | 2.4% | 10.9% | ||
| Q4 24 | 0.5% | 16.3% | ||
| Q3 24 | 7.2% | 14.3% |
净利率BZHRVTY
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | -9.0% | 12.7% | ||
| Q3 25 | 3.8% | 6.7% | ||
| Q2 25 | -0.1% | 7.5% | ||
| Q1 25 | 2.3% | 6.4% | ||
| Q4 24 | 0.7% | 13.0% | ||
| Q3 24 | 6.5% | 13.8% |
每股收益（稀释后）BZHRVTY
| Q2 26 | $-0.03 | — | ||
| Q1 26 | $-1.13 | — | ||
| Q4 25 | $-1.13 | $0.86 | ||
| Q3 25 | $1.01 | $0.40 | ||
| Q2 25 | $-0.01 | $0.46 | ||
| Q1 25 | $0.42 | $0.35 | ||
| Q4 24 | $0.10 | $0.77 | ||
| Q3 24 | $1.69 | $0.77 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $116.4M | $919.9M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $1.2B | $7.3B |
| 总资产 | $2.8B | $12.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资BZHRVTY
| Q2 26 | $116.4M | — | ||
| Q1 26 | $120.8M | — | ||
| Q4 25 | $120.8M | $919.9M | ||
| Q3 25 | $214.7M | $931.4M | ||
| Q2 25 | $82.9M | $991.8M | ||
| Q1 25 | $85.1M | $1.1B | ||
| Q4 24 | $80.4M | $1.2B | ||
| Q3 24 | $203.9M | $1.2B |
股东权益BZHRVTY
| Q2 26 | $1.2B | — | ||
| Q1 26 | $1.2B | — | ||
| Q4 25 | $1.2B | $7.3B | ||
| Q3 25 | $1.2B | $7.4B | ||
| Q2 25 | $1.2B | $7.6B | ||
| Q1 25 | $1.2B | $7.6B | ||
| Q4 24 | $1.2B | $7.7B | ||
| Q3 24 | $1.2B | $7.9B |
总资产BZHRVTY
| Q2 26 | $2.8B | — | ||
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.6B | $12.2B | ||
| Q3 25 | $2.6B | $12.1B | ||
| Q2 25 | $2.7B | $12.4B | ||
| Q1 25 | $2.7B | $12.4B | ||
| Q4 24 | $2.6B | $12.4B | ||
| Q3 24 | $2.6B | $12.8B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $182.0M |
| 自由现金流经营现金流 - 资本支出 | — | $161.8M |
| 自由现金流率自由现金流/营收 | — | 21.0% |
| 资本支出强度资本支出/营收 | — | 2.6% |
| 现金转化率经营现金流/净利润 | — | 1.85× |
| 过去12个月自由现金流最近4个季度 | — | $509.4M |
8季度趋势，按日历期对齐
经营现金流BZHRVTY
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $-165.3M | $182.0M | ||
| Q3 25 | $250.2M | $138.5M | ||
| Q2 25 | $-62.3M | $134.3M | ||
| Q1 25 | $3.4M | $128.2M | ||
| Q4 24 | $-159.4M | $174.2M | ||
| Q3 24 | $185.4M | $147.9M |
自由现金流BZHRVTY
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $-170.9M | $161.8M | ||
| Q3 25 | $242.7M | $120.0M | ||
| Q2 25 | $-70.2M | $115.5M | ||
| Q1 25 | $-4.4M | $112.2M | ||
| Q4 24 | $-164.6M | $149.8M | ||
| Q3 24 | $179.8M | $125.6M |
自由现金流率BZHRVTY
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | -47.0% | 21.0% | ||
| Q3 25 | 30.6% | 17.2% | ||
| Q2 25 | -12.9% | 16.0% | ||
| Q1 25 | -0.8% | 16.9% | ||
| Q4 24 | -35.1% | 20.5% | ||
| Q3 24 | 22.3% | 18.4% |
资本支出强度BZHRVTY
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.5% | 2.6% | ||
| Q3 25 | 0.9% | 2.6% | ||
| Q2 25 | 1.5% | 2.6% | ||
| Q1 25 | 1.4% | 2.4% | ||
| Q4 24 | 1.1% | 3.4% | ||
| Q3 24 | 0.7% | 3.3% |
现金转化率BZHRVTY
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | 1.85× | ||
| Q3 25 | 8.34× | 2.97× | ||
| Q2 25 | — | 2.49× | ||
| Q1 25 | 0.27× | 3.03× | ||
| Q4 24 | -50.92× | 1.84× | ||
| Q3 24 | 3.56× | 1.57× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BZH
| West region | $231.3M | 56% |
| East region | $90.8M | 22% |
| Southeast region | $75.7M | 18% |
| Land sales and other | $12.1M | 3% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
